GSK and Roche get EU breast cancer indication
August 15, 2013Sales and Marketing GSK, Herceptin, Roche, Tyverb, Xeloda, breast cancer
The European Commission has granted a new indication for the use of GSK’s breast cancer drug Tyverb in combination with …
Celgene’s multiple myeloma pill launched in UK
August 15, 2013Sales and Marketing Celgene, Velcade, low, myeloma
Celgene’s new oral blood cancer drug pomalidomide has been launched in the UK and Ireland as a third line treatment …
ABPI publishes trial disclosure ‘toolkit’
August 15, 2013Medical Communications, Sales and Marketing ABPI, EFPIA, Goldacre, transparency
The ABPI has today launched a new clinical trial disclosure toolkit to help pharma companies meet data transparency requirements. The …
Astellas hires senior VP from rival Takeda
August 15, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Takeda, oncology
Astellas has appointed Claire Thom from fellow Japanese firm Takeda to be senior vice president of its global oncology development. …
HIV pill Tivicay gains FDA approval
August 14, 2013Sales and Marketing FDA, GSK, Tivicay, ViiV
ViiV and partner GlaxoSmithKline’s new HIV drug Tivicay has been shown the FDA’s green light for distribution in the US. …
Phoenix from the flames for Lilly cancer drug
August 14, 2013Research and Development, Sales and Marketing NSCLC, lilly, lung cancer, necitumumab
A drug that once looked doomed to fail has shocked analysts by helping late-stage lung cancer patients live longer. Necitumumab …
New president and chief executive for EMMES
August 14, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMMES
Research support firm The EMMES Corporation has announced that its executive VP Dr Anne Lindblad has been promoted to president …
FDA project will examine abuse-resistant formulations
August 13, 2013Manufacturing and Production API, CDC, FDA
The FDA is seeking tenders for a research project to examine how effective tamper-resistant formulations of opioid analgesics really are …
The new NHS: a marriage of inconvenience?
August 13, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CCG, NHS England, andy lee, market access, quarry house
As NHS England tries to squeeze more money out of the healthcare budget to pay for specialist commissioning, Andy Lee …
Rebrand for Just:: comms agency
August 13, 2013Medical Communications Just:: Health
London-based healthcare agency Just:: Health PR has changed its name to Just:: Health Communications. The move is in response to …
Vical melanoma drug dropped
August 13, 2013Research and Development, Sales and Marketing Vical, allovectin, melanoma
Vical has abandoned trials of a late-stage drug for the deadliest form of skin cancer after the treatment failed to …
Bribery ‘routine’ for pharma in China
August 13, 2013Sales and Marketing BBC, China, GSK, Sanofi, bribery, drug reps
Sanaria’s malaria vaccine shows promise
August 9, 2013Research and Development, Sales and Marketing PfSPZ, Vaccine, malaria, sanaria
Researchers in the US have announced promising results from a Phase I clinical trial of biotech firm Sanaria’s new malaria …
AllTrials campaign releases manifesto
August 9, 2013Medical Communications, Research and Development, Sales and Marketing Bad pharma, GSK, Goldacre, NICE, transparency
The UK clinical trial transparency initiative AllTrials has released its first detailed manifesto as it looks to ramp up pressure …
Ranbaxy taps into Malaysian growth with second facility
August 9, 2013Manufacturing and Production ASEAN, Ranbaxy, asian, malaysian
Indian drugmaker Ranbaxy has signed a deal to construct a new $35 million manufacturing facility in Malaysia that will triple …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
